Le Lézard
Classified in: Science and technology
Subject: TRADE ISSUES

Trading of RSI Shares to Move to NEX Exchange


VANCOUVER, British Columbia, Aug. 09, 2019 (GLOBE NEWSWIRE) -- RSI International Systems Inc. (TSX-V: RSY) ("RSI" or the "Company") updates that as originally announced May 13, 2019, listing of the Company's shares is being moved from the TSX-V, to the NEX, a separate board of the TSX-V. It is expected that trading of RSI shares on the TSX-V will cease at market close on Monday, August 12, 2019 and commence trading on the NEX at market open on Tuesday, August 13, 2019.

RSI President and CEO, Adam Ho stated "Although the sale of our principal business in February this year has given us $5 million to invest in a new business, we do not currently have an active business as defined by the TSX-V continuous listing requirements and hence the change in listing." 

Mr. Ho concluded "Our expectations of the process for us to invest in a new business are that there is no real difference whether we are listed on the TSX-V or NEX. Accordingly, we remain focused on minimizing our costs and finding a good business to acquire at a reasonable price, so that we may deliver value to our shareholders."

RSI has approximately $5 million available to invest in a new business or asset. With funds already in hand and a supportive major shareholder holding over 44% of RSI's outstanding shares, the Company believes that it offers an attractive opportunity to companies seeking investment, given the reduction of financing and other transaction risks. RSI encourages all cash flowing businesses seeking a public listing or investment into their company, to contact management to discuss a potential transaction.

With the transition from the TSX-V to the NEX, the Company's trading symbol will change from RSY to RSY.H.  There is no change in the Company's name, its CUSIP number and there is no consolidation of capital. The NEX is a separate board of the TSX-V.

Neither the TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this release.

About RSI 
RSI International Systems Inc. has recently sold its only business asset, RoomKeyPMS. The Company is now seeking to use the net sale proceeds to invest in a new business.

Cautionary Note Regarding Forward Looking Statements
This news release contains forward-looking statements. Any statements that are not strictly historical fact are considered "forward-looking statements." Forward-looking statements cannot be guaranteed and involve assumptions and are subject to a variety of risks and uncertainties which could cause actual events or results to materially differ from those reflected in the forward-looking statements. Readers are advised to rely on their own evaluation of such risks and uncertainties and not place undue reliance upon forward-looking statements. Any forward-looking statements made herein are made as of the date hereof, and the Company assumes no obligation and disclaims any intention to revise or update any forward-looking information and statements except as required by applicable laws.

For more information, please contact:

RSI International Systems Inc.
Adam Ho, President, CEO & Director
(604) 329-1009

 


These press releases may also interest you

at 16:05
Aptose Biosciences Inc. ("Aptose" or the "Company") , a clinical-stage precision...

at 16:05
ProMIS Neurosciences Inc. , a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic...

at 16:05
REGULATED INFORMATION Nyxoah Reports First Quarter 2024 Financial and Operating ResultsAnnounced DREAM U.S. pivotal study achieved primary endpoints On track for FDA approval as early as end of 2024 Mont-Saint-Guibert, Belgium ? May 14, 2024...

at 16:05
Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung...

at 16:05
BeiGene, Ltd. , a global oncology company, today announced it will share new data from its hematology portfolio and pipeline at the European Hematology Association 2024 Hybrid Congress (EHA2024) in Madrid, Spain, June 13-16, 2024. BeiGene has 28...

at 16:05
Akili, Inc. , a leading digital medicine company, today reported its financial results for the quarter ended March 31, 2024 and provided an update on business progress. As announced in late April 2024, the Company's board of directors has initiated...



News published on and distributed by: